Introduction
Plasmablastic lymphoma (PBL) was first reported by Delecluse in 1997 as commonly arising in the oral cavity of HIV-positive patients [1] . The histologic appearance was similar in the 16 described cases, with lamina propria of the oral mucosa infiltrated by a diffusely growing cellular population. Despite minimal expression of the B cell antigen CD20, B cell nature and clonal origin were finally demonstrated. With cells showing an immunoblast morphology and an immunophenotype of a plasma cell, this tumor was named PBL. Eleven years later, the WHO classification recognized PBL as a rare variant of diffuse large B-cells lymphoma, accounting for 2% of acquired immune deficiency syndrome (AIDS)-related lymphoma [2] . A greater diversity of both sites and setting has been described since the original report including post-transplant patients and other immunodeficiencies [3] , but also immunocompetent patients [4, 5] . However, due to the rarity of this disease, most clinical data derive from pooled case reports and small series. A clinically aggressive course is usually reported, without consensus of treatment. The aim of this study was to collect cases of PBL reported in LYmphoma Study Association (LYSA) centers to better identify features of PBL, analyze therapeutic approaches and prognostic factors.
Methods

Patients selection
Patients diagnosed as PBL identified by clinicians members of the LYSA were selected. Clinical data including sex, age, medical history, OMS score, tumor site, bone marrow (BM) biopsy and Ann Arbor stage were recorded. Treatment strategy and response assessment according to the international workshop criteria including CT-scan and 18-FDG-PET/CT were reported [6, 7] . Biological data included hemogram, LDH level, electrophoresis of protein, EBV DNA loads measured by quantitative polymerase chain reaction. The main immunohistochemical markers (CD20, CD79a, CD30-cutoff threshold of 20%-CD38, CD138 and MUM1) were reviewed, as well as Ki67 and EBV-encoded small RNA (EBER) expression by in situ hybridization, HHV8, ALK and MYC expression. No systematic centrally biopsy review was required to be included as most patients were included in the lymphopath review process [8] , a systematic review of all lymphoma cases promoted by the French National Cancer Agency.
Statistical analysis
Patient characteristics were compared using the v 2 test. Event-free survival (EFS) was calculated from the date of diagnosis to the date of death, progression or primary treatment failure. Overall survival (OS) was defined as the time from diagnosis until the date of death or last followup. Survival curves were generated using the Kaplan-Meier method and were compared by the log-rank test. Multivariate analysis was carried out using Cox regression methods. Statistical analyses were carried out at the conventional two-tailed a level of 0.05, using R software version 3.0.2 (R foundation for statistical computing, Vienna, Austria).
Results
Clinical, biological and morphological features
Among 160 collected cases, 8 were excluded for uncertain diagnosis and 17 (11%) for missing data. Ultimately, 135 patients were included from French and Belgium centers, diagnosed as PBL between 2000 and 2015.
Global population. Most patients were men with a median age of 58 years (Table 1) . Patients were categorized on the basis of their immunologic status as follows: HIV-positive patients (56/135, 42%), post-transplant patients (17/135, 12%) and HIV-negative/ non-transplanted patients (62/135, 46%). The most frequent primary involved site was the oral cavity (19%). A monoclonal serum immunoglobulin was detected in 30 of the 83 (22%) tested cases (IgG in 18 cases). EBV DNA load was positive in 64% of tested patients (median 7500, range 0-2 Â 10 6 copies/ml). 18-FDG-PET/CT was carried out in 69 patients and showed avidity in all tumor sites, with a median SUV max of 10 (range 3-50).
HIV-positive patients. With a median age of 46 years, the 56 HIVpositive patients were significantly younger (P < 0.0001). PBL was the first manifestation of HIV infection in 11 patients. Median time between diagnosis of HIV infection and PBL was 4 years (range 0-28 years). T-CD4 cell count was lower than 0.2 g/l in 43% of patients (median 0.23 g/l, range: 0.13-1.10 g/l). HIV viral load was >10 5 copies/ml in 24% of cases, and was <50 copies/ml in 20 of the 35 patients receiving cART at the time of PBL diagnosis.
Post-transplant patients. Median age of solid organ transplant patients was 55 years. Site of transplantation was renal (nine cases), renal and pancreatic (two cases), cardiac (five cases) and lung (one case). Median time between transplantation and PBL diagnosis was 12 years (range 0-24 years). Transplanted kidney was the primary involved site in four cases.
HIV-negative/non-transplanted patients. The 62 remaining patients were significantly older than other patients (71 versus 47 years, P < 0.001). Among these patients, four sub-groups were distinguished. First, medical histories revealed autoimmune or chronic inflammatory systemic disease in seven cases (sarcoidosis, inclusion body myositis, severe cutaneous psoriasis, Basedow disease, Horton disease and two cases of rheumatoid arthritis). Thirteen patients had a history of malignancy. Interestingly, four other patients had developed PBL on a localized inflammatory site (perineal tumor in the setting of recurrent anal fistula, gluteal skin abscess involvement in the setting of recurrent acne conglobata, stomach involvement in the setting of chronic gastritis and small intestine involvement in the setting of celiac disease). Among the remaining 38 patients, 31 were older than 60 years, considered patients in which increased age correlates with senescence in immunity [11] . Ultimately, immunosuppressive factors, localized, systemic or other forms of an attenuated immune system were absent in only seven patients of the entire cohort.
Immunohistochemical findings
Histopathological review was carried out in 120 cases (89%). Plasma cell markers CD138 and MUM1 were present, respectively, in 88% and 96% of tested cases ( Table 1) . The plasmablastic cells were frequently negative for B cell markers, but a weak positivity of CD20 was noted in 10% of cases. ALK expression was negative in 21 of the 22 tested cases and CD30 positive in 20% of cases.
EBER expression was observed in 62% of tested cases (cutoff value of 20%), more frequently in immunocompromised patients (P < 0.0001). Among the 18 cases assessed for MYC expression, 11 were positive.
Treatment modalities
Chemotherapy was administered to 108 of 135 patients (80%). The most commonly used regimen was CHOP or CHOP-like, in 70 cases. Sixteen patients received anthracycline-based intensive regimen like ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone), EPOCH (dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone), COPADM (cyclophosphamide, vincristine, prednisone, adriamycin, high-dose methotrexate). A combination of bortezomib and anthracyclin was administered in six patients. Ten patients including nine elderly patients received a reduced dose regimen with no anthracyclines. The six remaining patients received different chemotherapy regimens. Six patients who achieved CR after chemotherapy underwent autologous hematopoietic stem cell transplantation (HSCT).
Rituximab was given in 25 cases (18%) (monotherapy for 2 cases, immuno-chemotherapy for 23 cases). Four patients have received radiotherapy alone, as palliative care. Curative surgical resection was the single treatment in two cases with localized disease (thyroidectomy for a thyroid involvement and transplantectomy for a renal graft involvement).
Nineteen patients (14%) did not receive any form of therapy for PBL because of early death or primary palliative care.
Response to treatment
Fifty five percent of treated patients achieved a complete response (CR), 5% a partial response, 2% a stable disease, 19% showed a primary progressive disease, 12% died during first line therapy (9 from chemotherapy toxicity, 5 from lymphoma). The remaining patients (7%) were not assessable.
CR rate was not significantly higher in patients receiving intensive base anthracyclin regimen compared with patients receiving CHOP therapy. Among the 6 patients who received autologous HSCT in the first CR, 3 remained relapse-free at last follow-up (13, 17 and 29 months after HSCT), 2 patients had relapsed at 8 and 26 months, and 1 died from another cause after 78 months of remission.
Rituximab monotherapy and radiotherapy alone were inefficient with one early relapse and one primary progression. When combined with chemotherapy, rituximab showed a trend toward significativity for improving CR rate compared with chemotherapy alone (P ¼ 0.08). The two patients treated by surgery alone achieved durable CR, although one patient relapsed after 4 years of follow-up. Results are reported on total number of patients for each category, except when data were available only for a subset of patients which number is specified after slash.
In four HIV-patients, instauration of cART alone failed to induce a sustained hematological response with progression at 1, 2, 3 and 5 months, despite an initial clinical regression of tumor in three cases.
In the chemotherapy-treated patients group, achievement of a CR correlated with low or low intermediate IPI score (0-2 points), absence of BM involvement (P < 0.0001), absence of CD30 expression (P ¼ 0.009), HIV positive status (P ¼ 0.05). Relapse after CR was observed in 23% of patients, at an average time of 23 months (range 8-73).
Clinical outcome and prognosis parameters
The median follow-up was 49 months with five patients lost to follow-up. At last follow-up, 53% of patients were died. Deaths were related to lymphoma progression (68%), treatment-related toxicity (15%), other reasons (10%) or unknown (7%). Median OS and EFS were 32 and 22 months, respectively. HIV-positive patients showed a median OS not reached, whereas transplantpatients and HIV-negative/nontransplanted patients showed a median OS of 32 and 16 months, respectively (Figure 1) .
Prognostic factors by univariate analysis are reported in Table 2 . HIV positivity and EBER expression were significantly associated with better OS (P ¼ 0.024 and 0.005, respectively). IPI score was strongly correlated with OS and EFS (P < 0.0001) [low (0-2) versus high (3-5) risk]. Chemotherapy and CR achievement correlated with OS (P < 0.0001) (Figure 2 ). Among chemotherapy-treated patients, use of rituximab tends to be associated with a better EFS (P ¼ 0.06). Benefit of rituximab was not associated with CD20 or EBV positivity. Autograft and anthracyclinebased intensive regimens were not associated with significant benefit. In HIV associated PBL, T-CD4 cells count did not correlate significantly with survival.
In multivariate analysis, OS was found to correlate with IPI score (HR ¼ 0.46, IC 95% ¼ 0.25-0.82, P ¼ 0.01) (low versus high) and achievement of a CR (HR ¼ 0.148, IC 95% ¼ 0.08-0.29, P < 0.0001). EFS correlated with IPI score (HR ¼ 0.23, IC 95% ¼ 0.14-0.40, P < 0.001).
Discussion
This cohort of 135 patients is the largest reported to date with exhaustive collected data and long follow-up. We confirmed that PBL patients are characterized by male predominance, predilection of oral cavity involvement, and a high prevalence of immunocompromised patients [9, 10] . Due to retrospective data, multicentric center study and diverse therapeutic approaches, this study shows, however, some potential biases.
HIV positive patients accounted for 42% of cases, similar to a recent published series [11] but lower than usually reported in literature reviews [10, 12] . More than half of the HIV patients received cART therapy and presented a CD4 cells count superior than 0.2 g/l, suggesting that PBL can occur without severe immunosuppression. The 17 cases of this series represent the largest cohort of PBL in post-transplant patients, usually accounting for only 5%-6% in other series or reviews [10, 11, 13] . The majority of HIV-negative/non-transplanted patients, finally presented with different degrees of immunosuppression, including four cases of PBL arising in the setting of chronic localized inflammatory disorders. This latter finding has never been described in the setting of PBL occurring in patients who seemed, at first sight, immunocompetent. Ultimately, only 5% of patients did not show evidence of immune modulation, confirming the close links between immunosuppression and PBL.
There is no standard of care defining optimal therapeutic approach. CHOP is the most commonly use regimen, however, NCCN guidelines state that it is not adequate therapy and recommends more intensive regimen [14] . These guidelines are based on small series and case reports. Autologous HSCT in first CR, assessed in only few case reports is thought to be a feasible option [15] . In this cohort, anthracycline-based intensive regimen as well as autologous SCT did not show significant benefit in OS and EFS, potentially because few patients were concerned. The benefit of rituximab, added to chemotherapy, remains uncertain, although there was a trend toward improved CR rate and EFS, compared with chemotherapy alone. Concerning PBL HIV positive patients, use of cART combined with chemotherapy show benefit in OS in a large meta-analysis [16] , in line with data on the management of AIDS-related lymphoma [17] . An important finding in our cohort was the inefficacity of c-ART alone to achieve sustained CR. Few case reports described spontaneous regression of PBL with c-ART, but showed early relapse or insufficient follow-up to conclude on the efficacy of this strategy [18, 19] and should not be then recommended.
Poor survival has been largely reported with median OS time ranging between 6 and 19 months [5, 15, [20] [21] [22] . With a median OS of 32 months, the outcome of our cohort was longer but remained poor. Many intrinsic features of PBL, such as recurrent MYC rearrangement, plasmablastic morphology and lack of Original article Annals of Oncology CD20, are known as poor prognosis factors in other lymphomas [23] [24] [25] and could explain such prognosis. Localized disease, use of chemotherapy and achievement of CR were confirmed to be good prognostic factors in the univariate analysis, consistent with other studies [5, 12, 21, 26] . Interestingly, HIV status conferred a better prognosis in PBL patients in our study, in accordance with a literature review [12] . Hypotheses to explain this finding are an immune surveillance restoration by c-ART and their younger age, giving them a higher chance of receiving an aggressive chemotherapy. Among HIV patients, prognostic factors were those of lymphoma rather than those of HIV.
The IPI score has been assessed in only two cohorts of HIVpositive patients, showing a significant impact on prognosis, by univariate analysis [27, 28] . Our results confirm this data for the entire cohort and found also that achievement of a CR significantly correlated with OS.
In conclusion, our study illustrates that the spectrum of patients with PBL extends beyond HIV positive or post-transplant patients with a significant proportion of cases arising in the setting of other immune disorders, leaving little margin for immunocompetent patients. Considering clinical and biological features at diagnosis, it seems that a prolonged-rather than a profound-immunosuppression is needed to develop PBL. Despite the poor outcome, prolonged remission is possible, mainly with chemotherapy. R-CHOP seems to be a good backbone for future studies that aim to improve prognosis with new agents. 
